The Central Nervous system and Infection by Candida Species
Diagn Microbial Infect Dis 37:169-179, Sanchez-Portocarrero, J.,et al, 2000
Fungal Meningitis
Semin Neurol 20:307-322, Gottfredsson, M. & Perfect J.R., 2000
Leukoencephalopathy and Raised Brain Lactate from Heroin Vapor Inhalation ("Chasing the Dragon")
Neurol 53:589-1048, Kriegstein,A.R., et al, 1999
Hypoxic/Ischaemic Brain Damages, Especially Pallidal Lesions, in Heroin Addicts
Forensic Sci Int 102:51-59, Andersen,S.N. &Skullerud,K., 1999
Cerebral Venous Thrombosis,Combined Intrathrombus rtPA and Intravenous Heparin
Stroke 30:489-494,481, Frey,J.L.,et al, 1999
Cerebral Venous Thrombosis,Nothing,Heparin,or Local Thrombolysis?
Stroke 30:481-483, Bousser,M-G, 1999
Serum Glucose Level and Diabetes Predict Tissue Plasminogen Activator-Related Intracerebral Hemorrhage in Acute Ischemic Stroke
Stroke 30:34-39, Demchuk,A.M.,et al, 1999
Evaluation of Early Computed Tomographic Findings in Acute Ischemic Stroke
Stroke 30:389-392, Marks,M.P.,et al, 1999
"Telestroke",The Application of Telemedicine for Stroke
Stroke 30:464-469, Levine,S.R.&Gorman,M., 1999
Intra-Arterial rtPA Treatment of Stroke Assessed by Diffusion- and Perfusion-Weighted MRI
Stroke 30:678-680, Lansberg,M.G.,et al, 1999
Improvement in Adult-Onset Rasmussen's Encephalitis with Long-Term Immunomodulatory Therapy
Neurol 52:738-742, Leach,J.P.,et al, 1999
Plasma Exchange Versus Intravenous Immunoglobulin Treatment in Myasthenic Crisis
Neurol 52:629-632, Qureshi,A.I.,et al, 1999
Course and Treatment of Myasthenia Gravis During Pregnancy
Neurol 52:447-452, Batocchi,A.P.,et al, 1999
"Toilet Seat" Sciatic Neuropathy
Arch Neurol 56:116, Holland,N.R.,et al, 1999
CT Angiography and Doppler Sonography for Emergency Assessment in Acute Basilar Artery Ischemia
Stroke 30:606-612, Brandt,T.,et al, 1999
Treatment of Absence Status with Intravenous Valproate
Neurol 52:889-890, Alehan,F.K.,et al, 1999
Diagnosis and Treatment of Ischemic Stroke
Am J Med 106:211-221, Alberts,M.J., 1999
Acute Vertebrobasilar Occlusion:Treatment with High-Dose Intraarterial Urokinase
AJR 172:709-712, Hoffman,A.I.,et al, 1999
Application of a Rheolytic Thrombectomy Device in the Treatment of Dural Sinus Thrombosis:A New Technique
AJNR 20:568-570, Dowd,C.F.,et al, 1999
Evidence of Anaphylaxy after Alteplase Infusion
Stroke 30:1142-1143, Rudolf,J.,et al, 1999
Neurologic Manifestations of AIDS in Older Adults
Infect Dis Clin Practice 8:179-185, Finelli,P.F.,et al, 1999
Outcome in Severe Pediatric Guillain-Barre Syndrome after Immunotherapy or Supportive Care
Neurol 52:1494-1497, Graf,W.D.,et al, 1999
Superselective Intraarterial Fibrinolysis in Central Retinal Artery Occlusion
AJNR 20:565-567, Padolecchia,R.,et al, 1999
Association of Hyperdense Middle Cerebral Artery Sign with Clinical Outcome in Patients Treated with Tissue Plasminogen Activator
Stroke 30:769-772, Manelfe,C.,et al, 1999
Hyperintense Basal Ganglia on T1-Weighted MR Imaging
AJR 172:1109-1115, Lai,P.H.,et al, 1999
Intracranial Stenoocclusive Disease:Double-Detector Helical CT Angiography versus Digital Subtraction Angiography
AJNR 20:791-799,731, Skutta,B.,et al, 1999
Evaluation of Early Reperfusion and IV tPA Therapy Using Diffuion- and Perfusion-Weighted MRI
Neurol 52:1792-1798,1733, Marks,M.P.,et al, 1999
Effects of Tissue Plasminogen Activator for Acute Ischemic Stroke at One Year
NEJM 340:1781-1787, Kwiatkowski,T.G.,et al, 1999
Applications of Diffusion-Perfusion Magnetic Resonance Imaging in Acute Ischemic Stroke
Neurol 52:1750-1756,1733, Fisher,M.&Albers,G.W., 1999
Initial Clinical Experience with IV Tissue Plasminogen Activator for Acute Ischemic Stroke:A Multicenter Survey
Neurol 53:424-427, Tanne,D.,et al, 1999
Consent Issues in the Management of Cerebrovascular Diseases, A Position Paper of the American Academy of Neurology Ethics and Humanities Subcommittee
Neurol 53:9-11, , 1999
Intraarterial Thrombolysis for Treatment of Acute Stroke:Experience in 26 Patients with Long-Term Follow-Up
AJNR 20:1291-1299, 1194, Jahan,R.,et al, 1999
Demyelinative Brainstem Encephalitis Responsive to Intravenous Immunoglobulin Therapy
Pediatrics 104:301-304, Assa,A.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Prognostic Factors of Guillain-Barre Syndrome After Intravenous Immunoglobulin or Plasma Exchange?
Neurol 53:598-604, Visser,L.H.,et al, 1999
Prevalence of Peripheral Neuropathy in Injection Drug Users
Neurol 53:592-597, Berger,A.R.,et al, 1999
Agreement and Variability in the Interpretation of Early CT Changes in Stroke Patients Qualifying for Intravenous rtPA Therapy
Stroke 30:1528-1533, Grotta,J.C.,et al, 1999
Pompholyx (Vesicular Eczema) After IV Immunoglobulin Therapy for Neurologic Disease
Neurol 53:1154-1155, Iannaccone,S.,et al, 1999
Intra-Arterial Cerebral Thrombolysis for Acutre Ischemic Stroke in a Community Hospital
AJNR 20:1682-1687,1580, Edwards,M.T.,et al, 1999
Predictors of Clinical Improvement,Angiographic Recanalization, and Intracranial Hemorrhage After Intra-Arterial Thrombolysis for Acute Ischemic Stroke
Stroke 30:2094-2100, Suarez,J.I.,et al, 1999
Therapeutic Plasma Exchange and Intravenous Immunoglobulin for Obsessive-Compulsive Disorder and Tic Disorders in Childhood
Lancet 354:1153-1158, Perlmutter,S.J.,et al, 1999
Expanding the Window for Thrombolytic Therapy in Acute Stroke, The Potential Role of Acute MRI for Patient Selection
Stroke 30:2230-2237, Albers,G.W., 1999
MRI Features of Intracerebral Hemorrhage Within 2 Hours from Symptom Onset
Stroke 30:2263-2267, Linfante,I.,et al, 1999
The Intensive Care Management of Acute Ischemic Stroke
The Neurologist 5:313-325, Deibert,E.&Diringer,M.N., 1999
Intra-Arterial Prourokinase for Acute Ischemic Stroke, The PROACT II Study:A Randomized Controlled Trial
JAMA 282:2003-2011, Furlan,A.,et al, 1999
Combined Intravenous and Intra-Arterial r-TPA Versus Intra-Arterial Therapy of Acute Ischemic Stroke, Emergency Management of Stroke (EMS) Bridging Trial
Stroke 30:2598-2605, Lewandowski,C.A.,et al, 1999
Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset, The ATLANTIS Study:A Randomized Controlled Trial
JAMA 282:2019-2026, Clark,W.M.,et al, 1999
Diffuse Cerebral Vasculitis with Normal Results on Brain MR Imaging
AJR 173:1494-1496, Imbesi,S.G., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999